1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Cariprazine is a D3-preferring D3/D2 receptor partial agonist under development for the treatment of schizophrenia, bipolar mania, and major depressive disorder by Hungary-based Gedeon Richter and Forest. While maintaining highest affinity for D3 receptors, cariprazine also has low potency at 5-HT2C, H1, and adrenergic receptor sites.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cariprazine for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cariprazine performance
- Obtain sales forecast for Cariprazine from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Diagnosis 14
4.1.1 Subjective Assessments 15
4.1.2 Disease Subtypes 16
4.2 Treatment Overview 18
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 21
4.2.2 Maintenance Treatment of Schizophrenia 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Opportunity and Unmet Need 26
6.1 Unmet Needs Overview 26
6.1.1 Public Awareness 27
6.1.2 Early Diagnosis and Treatment 29
6.1.3 Long-Acting and Advanced Drug Delivery Systems 30
6.1.4 Effective Management of Negative and Cognitive Symptom Domains 31
6.2 Gap Analysis 32
6.2.1 Long-Acting Drug Delivery 33
6.2.2 Treatment of Negative and Cognitive Symptoms 33
7 Pipeline Assessment 34
7.1 Overview 34
7.2 Early-Stage Pipeline Assessment 34
7.3 Novel Therapeutic Approaches 35
7.3.1 Negative Symptoms 36
7.3.2 Cognitive Symptoms 36
7.4 Long-Acting Drug Delivery 36
7.5 Technology Trends Analysis 37
7.6 Key Drugs in Clinical Development 38
8 Cariprazine 40
8.1 Overview 40
8.2 Efficacy 40
8.3 Safety 41
8.3.1 Dosing and Formulation 42
8.3.2 Potential Clinical Positioning 42
8.3.3 Potential Commercial Positioning 42
8.3.4 Pricing and Reimbursement 43
8.4 SWOT Analysis 43
8.5 Forecast 44
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 50
9.3 Methodology 53
9.4 Forecasting Methodology 53
9.4.1 Diagnosis and Treatment Rates 53
9.4.2 Adherence Rates 54
9.4.3 General Pricing Assumptions 54
9.4.4 Generic Erosion 55
9.4.5 Pricing of Pipeline Agents 55
9.5 Key Opinion Leaders 56
9.6 About the Authors 57
9.6.1 Author 57
9.6.2 Reviewers 57
9.6.3 Global Head of Healthcare 58
9.7 About GlobalData 59
9.8 Disclaimer 59

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 13
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 16
Table 3: Development-Based Classification of Antipsychotic Drugs 19
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 20
Table 5: Guidelines for the Treatment of Schizophrenia 21
Table 6: Leading Branded Treatments for Schizophrenia, 2013 25
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 25
Table 8: Unmet Needs - Current Level of Attainment 27
Table 9: Clinical Unmet Needs - Gap Analysis, 2013 32
Table 10: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014 37
Table 11: Pipeline Candidates in Development for Schizophrenia, 2014 38
Table 12: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013 39
Table 13: Product Profile - Cariprazine 40
Table 14: Cariprazine SWOT Analysis, 2014 43
Table 15: Global Sales Forecast ($m) for Cariprazine, 2012-2022 44

1.2 List of Figures

Figure 1: Schizophrenia - Pipeline Drugs by Target, 2014 35
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Antipsychotic Drugs Market Report 2016

Global Antipsychotic Drugs Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Antipsychotic Drugs Report is a professional and in-depth research report on the world's major regional market conditions of the Antipsychotic Drugs industry, focusing on the main regions (North ...

2016 Memantine hydrochloride (CAS 41100-52-1) Industry Market Report

2016 Memantine hydrochloride (CAS 41100-52-1) Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Memantine hydrochloride Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Memantine hydrochloride industry with ...

2016 Valproic Acid Industry Market Report

2016 Valproic Acid Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Valproic Acid Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Valproic Acid industry with a focus on the Chinese ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in the UK

  • November 2016
    11 pages
  • Antipsychotic  

  • United Kingdom  

View report >

Therapy Market in the US - Forecast

  • November 2016
    12 pages
  • Therapy  

  • United States  

    Brazil  

View report >

Therapy Market in the US

  • November 2016
    273 pages
  • Therapy  

    Obesity  

    Weight Loss  

  • United States  

View report >

Therapy Market

2 months ago

Related Market Segments :

Antipsychotic
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.